Smokers with mental illness are motivated to stop smoking and can quit successfully, usually without any exacerbation of their mental illness. GPs should be proactive in helping these patients to quit.

People with mental illness make up an increasing proportion of the smoking population. Although smoking rates in Australia have declined significantly in recent years, the prevalence of smoking in patients with mental illness remains high and is twice that of people without mental illness.

Nearly one in two Australian adults have a mental health disorder at some time in their lives. Patients with mental illness have poorer health and a shorter life expectancy than the rest of the population, and smoking is a major contributor to this health gap. Smoking also has a substantial financial impact. Smokers with schizophrenia may spend up to 30% of their limited income on cigarettes, sacrificing a healthier diet, social activities or medication in order to smoke.

Smokers with mental illness are less likely to be offered professional help to quit, in part because of the many myths and misconceptions about smoking in this population (Table 1).

For example, many health professionals mistakenly believe people with mental illness are not interested or are unable to quit, or that quitting will worsen their mental illness. However, smokers with mental illness are often highly motivated to quit, and GPs can be effective in helping them to do so.

This article examines the close link between smoking and mental illness, in particular anxiety disorders and depression, which are common in general practice, and schizophrenia and bipolar disorder in which smoking rates are highest. We explore the reasons for the high smoking prevalence in these disorders and the misinformation that has led to low intervention rates by health professionals. The evidence for treatment for smokers with specific mental illnesses is discussed, with practical advice to assist doctors in helping these smokers to quit.
Cigarette smoke also reduces the side effects of many psychotropic medications, such as sedation, by accelerating their metabolism and lowering blood levels.28

**Why Should People with Mental Illness Quit?**

**Health effects of smoking**

Smokers with mental illness have reduced life expectancy compared with people without mental illness and most of the excess mortality is due to smoking.3,10 They are far more likely to die from smoking-related disorders than from mental illness. They are far more likely to die from smoking-related disorders than from mental illness. The leading cause of premature death and illness in this population is cardiovascular disease, and smoking is the most significant contributing risk factor.4,5

Nicotine-dependent smokers also have a 77% increased risk of suicide attempts compared with nonsmokers.29 After a year’s abstinence, the risk of suicide drops dramatically.29 The quitting process itself is not associated with an increased risk of suicide.30

**The stress paradox**

Smokers often report that smoking helps them cope with stress. Nicotine has a transient anxiolytic action and can have a calming effect on the smoker. An additional benefit of a cigarette break is having time out and taking deep breaths while smoking.

However, smoking actually increases stress levels overall and former smokers often report feeling less stressed than when they smoked.8,20,31 Smokers experience frequent periods of nicotine withdrawal during the day between cigarettes and are often thinking about when and how they can smoke next. Much of the apparent calming effect of smoking is due to the relief of nicotine withdrawal.20 In addition, nicotine stimulates the release of hormones such as noradrenaline and cortisol, which can increase stress levels.26

GP’s should advise smokers that smoking is not an effective strategy for coping with stress. Healthier strategies should be discussed, such as time out without a cigarette, deep breathing, exercise, mindfulness, cognitive behavioural therapy or counselling.

**Can Smokers with Mental Illness Quit Safely?**

Smokers with mental illness can quit successfully but have lower quit rates than the general population.22 Smoking cessation strategies may be more challenging for this group because of their heavier smoking, higher levels of nicotine dependence and chronic stress.21,12 Other possible barriers to quitting include less social support and diminished cognitive and coping skills.

### TABLE 1. MYTHS ABOUT SMOKING AND MENTAL ILLNESS

<table>
<thead>
<tr>
<th>Myth</th>
<th>Fact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smokers with mental illness are not motivated to quit smoking</td>
<td>People with mental illness are at least as motivated to quit as the general population; 85% have tried to quit in the past (versus 78% without mental illness); and more than half are contemplating quitting within six months2,9,10</td>
</tr>
<tr>
<td>Smokers with mental illness are not able to quit smoking</td>
<td>Smokers with mental illnesses such as depression, schizophrenia and anxiety disorders can quit successfully but generally have lower quit rates11-13</td>
</tr>
<tr>
<td>Quitting smoking worsens mental illness</td>
<td>Quitting does not generally cause deterioration of mental illnesses such as depression, schizophrenia or post-traumatic stress disorder14-18</td>
</tr>
<tr>
<td>Smoking is a lower priority for patients with mental illness</td>
<td>Smokers with mental illness are more likely to die from smoking-related disease than from mental illness. Most of the excess mortality in smokers with mental illness is caused by smoking4</td>
</tr>
<tr>
<td>Smoking helps smokers cope with stress</td>
<td>Smoking increases stress levels overall. Former smokers often report feeling less stressed than when they were smokers14,20</td>
</tr>
</tbody>
</table>
Health professionals are often reluctant to encourage quitting because of concerns that it will exacerbate mental illness. However, there is good evidence these fears are mostly unfounded.

The same evidence-based therapies used in the general population are recommended for smokers with mental illness. However, counselling and support may need to be more intensive or prolonged. Additional help may be needed to address issues relevant to the mental illness, such as coping skills for stress and management of negative mood caused by quitting. Also, because of higher levels of nicotine dependence, many smokers with mental illness will require higher doses of medications used to aid smoking cessation, combination pharmacotherapy and a longer duration of therapy.

**EFFECT OF QUITTING ON PSYCHOTROPIC DRUG LEVELS**

Chemicals in tobacco smoke accelerate the metabolism of many common psychotropic medications, including antipsychotics, antidepressants and benzodiazepines, by induc-

EFFECT OF QUITTING ON PSYCHOTROPIC DRUG LEVELS

ing the cytochrome P450 enzyme, CYP1A2 (Table 2). This can substantially lower the serum concentrations and effectiveness of these medications in smokers.

Conversely, smoking cessation increases blood levels of these medications. Patients who quit smoking should be monitored for adverse effects, and dose reductions may be required. Immediate dose reductions should be considered for medications with a narrow therapeutic index, such as olanzapine and clozapine, to avoid medication toxicity.

Special care should be taken with bupropion because of potential interactions with other psychotropic medications. In particular, the risk of seizure may be increased when bupropion is combined with antidepressants or antipsychotics.

**SMOKING AND SPECIFIC ILLNESSES**

**Anxiety disorders**

Anxiety disorders (generalised anxiety disorder, post-traumatic stress disorder, panic disorder, agoraphobia, simple phobia and social phobia) comprise the largest mental health diagnostic group among smokers. People with anxiety disorders have approximately double the smoking rate of the general population. They have higher levels of nicotine dependence, more severe withdrawal and lower quit rates.

A large trial in patients with anxiety disorders demonstrated a 28% quit rate at six months, compared with 36% for smokers without an anxiety disorder. Modest results were also found in another study in post-traumatic stress disorder.

Anxious smokers should be taught alternative ways to manage their anxiety (see The stress paradox above). There is no evidence to support the use of anxiolytics to assist in quitting.

**Depression**

People with depression are twice as likely to smoke as those without depression, and they smoke more cigarettes per day. However, they are highly motivated to quit, possibly more than smokers in the general population. A meta-analysis of 42 trials found that smokers with a history of depression had a 19% lower rate of long-term abstinence compared with smokers without a history of depression. Quit rates are lower in those with recurrent depression than in those with a single episode.

Smokers with a history of depression may experience more severe negative mood, cravings and withdrawal symptoms when they quit. However, studies show no increase in relapse of major depression or suicide as a result of quitting. On the contrary, some studies report an improvement in mood after treatment.

Nicotine replacement therapy is effective in patients with depression, with similar quit rates to the general population. Bupropion appears to be equally effective in smokers with and without a history of depression. Bupropion has been linked to depression and suicide although causality has not been proven.

There has been limited research to date on the use of varenicline in patients with depression. However, no increase in psychiatric events has been found in trials in the general population and in patients with mental illness. There have been post-marketing case reports of depressed mood, agitation, changes in behaviour, suicide ideation and suicide in patients using varenicline.

Figure. Rates of smoking and average number of cigarettes per day by mental illness status in Australia (based on South Australian data for 2005–2007). Severe mental illness is defined as receiving a disability pension on the basis of a psychological or psychiatric illness.
varenicline. These are also symptoms of nicotine withdrawal, and a causal relationship with varenicline has not been demonstrated. Patients should be advised of a possible risk and monitored regularly for mood or behaviour changes.

The addition of cognitive behavioural therapy for mood management to conventional smoking cessation treatment for patients with a history of depression has also been shown to enhance success rates.

Schizophrenia
Seventy per cent of patients with schizophrenia smoke, and they smoke more intensely than other smokers. However, they are at least as motivated to quit as the general population. Nevertheless, smokers with schizophrenia have overall quit rates that are only about half those of the general population. Smoking cessation does not generally cause a deterioration in their mental health. Varenicline appears to be safe, well tolerated and effective in trials to date in people with schizophrenia, although there have been some case reports of increased psychiatric symptoms. Varenicline should be used with caution in this group until further research results are available.

Bipolar disorder
Although 60% of patients with bipolar disorder smoke, there have been no published studies of smoking cessation in these patients. Standard treatments are recommended, although more intensive counselling may be beneficial. Bupropion should be used only in conjunction with a mood stabiliser.

CONCLUSION
Smokers with mental health disorders comprise a large proportion of the Australian smoking population, and their smoking is often neglected by healthcare providers. However, smoking is the major contributor to the excess disease burden in this group. GPs need to proactively address this hidden epidemic. Smokers with mental illness are motivated to stop smoking and can quit successfully, usually without any exacerbation of their psychiatric condition. The same evidence-based interventions used for the general population are recommended, with some special considerations in the choice of pharmacotherapy. More intensive or prolonged counselling, support and pharmacotherapy may give better results.

REFERENCES
A list of references is included in the website version (http://www.medicinetoday.com.au) and the iPad app version of this article.

COMPETING INTERESTS: Dr Mendelsohn has received honoraria for teaching, consulting and travel from Pfizer, GlaxoSmithKline and Johnson and Johnson. He sits on Pfizer’s Champix Advisory Board and has served on GlaxoSmithKline’s Nicotine Replacement Therapy Expert Panel. Dr Montebello has received honoraria for teaching, consulting and travel from Pfizer and sits on Pfizer’s Champix Advisory Board.

TABLE 2. EFFECT OF SMOKING CESSATION ON BLOOD LEVELS OF PSYCHOTROPIC MEDICATIONS

<table>
<thead>
<tr>
<th>Medication</th>
<th>Effect of smoking cessation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antipsychotics</td>
<td></td>
</tr>
<tr>
<td>Olanzapine, clozapine</td>
<td>Blood levels increase; therefore reduce dose by about a third after quitting</td>
</tr>
<tr>
<td>Haloperidol, chlorpromazine, fluphenazine</td>
<td>Blood levels increase</td>
</tr>
<tr>
<td>Antidepressants</td>
<td></td>
</tr>
<tr>
<td>Duloxetine</td>
<td>Blood levels increase by 30%</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>Blood levels increase by 25%</td>
</tr>
<tr>
<td>Tricyclic antidepressants</td>
<td>Blood levels increase</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>Blood levels increase</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td></td>
</tr>
<tr>
<td>Alprazolam, oxazepam, diazepam</td>
<td>Blood levels increase</td>
</tr>
</tbody>
</table>

Online CPD Journal Program
Are patients with mental illness less motivated to quit smoking than those without mental illness?
Review your knowledge of this topic and earn CPD/PDP points by taking part in MedicineToday’s Online CPD Journal Program.
Smokers with mental illness
Breaking down the myths

COLIN MENDELSON MB BS(Hons)
MARK E. MONTEBELLO MB BS, FRANZCP, FACHAM

REFERENCES


34. Smokingcessation (accessed July 2013).